Get the latest news, insights, and market updates on TNYA (Tenaya Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201 Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression Completed Dosing in Cohort 2 of RIDGE™-1 Trial of TN-401 for PKP2-associated ARVC; Cohort 1 Data On Track for Fourth Quarter Company Presentation Tenaya Management to Review New MyPEAK-1 D Nov 10, 2025 - $TNYA
Tenaya Therapeutics (TNYA): Evaluating Valuation After Investor Buzz on MyPEAK-1 and RIDGE-1 Clinical Updates
Tenaya Therapeutics (TNYA) caught investors’ eyes following its CEO’s presentation at the Cell & Gene Meeting on the Mesa. Ongoing anticipation centers on clinical updates for the MyPEAK-1 and RIDGE-1 trials. See our latest analysis for Tenaya Therapeutics. After a flurry of interest sparked by the Mesa conference and anticipation for upcoming trial updates, Tenaya Therapeutics’ share price has rocketed, boasting a 195.7% return over the last 90 days. That short-term momentum stands out even... Oct 10, 2025 - $TNYA
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on Tuesday, October 14, 2025. Company management will host vir Oct 9, 2025 - $TNYA
Can Tenaya Therapeutics’ Leadership Messaging Shape Long-Term Perceptions and Value Creation for TNYA?
Tenaya Therapeutics recently took part in the Cell & Gene Meeting on the Mesa 2025 in Phoenix, where CEO Faraz Ali presented on October 6th. The company's participation at this prominent conference highlights the importance of leadership communication in shaping industry perceptions and future opportunities. We'll explore how insights shared by Tenaya's top executives may influence the company's investment narrative going forward. Explore 26 top quantum computing companies leading the... Oct 9, 2025 - $TNYA
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the following October investor and industry conferences. Details are below: Cell & Gene Meeting on the Mesa Date: Monday, October 6Time: 8 Oct 2, 2025 - $TNYA
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 202,000 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options ha Sep 18, 2025 - $TNYA
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 pm ET. The live web Sep 2, 2025 - $TNYA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple